News & Press Releases

DULUTH, GA, & LONDON, UK - August 27, 2026 - Bridge to Life™ Ltd., a global leader in organ preservation solutions and perfusion technologies, today highlighted the recent release of [...]

Financing will further accelerate the already successful early commercial rollout of VitaSmart™ HOPE System Company also advancing an active organ viability assessment tool designed to raise industry standards with a [...]

Studies in human uterus and small intestine transplants, including head-to-head comparison with normothermic oxygenated perfusion, presented at 2026 Annual Meeting of the American Transplant Congress (ATC) in Boston Duluth, GA [...]

To the Organ Transplantation Community, 2026 has already marked a transformative period for liver transplantation and organ preservation. Earlier this year, the U.S. Food and Drug Administration granted De Novo [...]

Presentations to highlight Hypothermic Oxygenated Perfusion (HOPE) with VitaSmart™ in human uterus and small intestine transplants, the latter comparing HOPE with normothermic oxygenated perfusion Duluth, GA June 10, 2026 - [...]

Clinical data show meaningful increases in organ utilization, unlocking new transplant supply in a market constrained by donor shortages Results demonstrate HOPE expands use of marginal donor organs, increasing transplant [...]

Bridge to Life highlights study presented as oral late-breaking clinical trial during “The 2026 International Congress of the International Liver Transplantation Society (ILTS)” in Geneva, Switzerland, May 6-9, 2026 Duluth, [...]

Studies presented as part of "The 2026 International Congress of the International Liver Transplantation Society (ILTS)" in Geneva, Switzerland, May 6-9, 2026 Presentations further support use of HOPE in U.S. [...]

Presentations to highlight hypothermic oxygenated perfusion (HOPE) with VitaSmart™ in liver transplants, including pediatric patients and partial grafts Duluth, April 28, 2026  Bridge to Life™ Ltd., a global innovator in [...]

Study presented in oral session at the 30thAnnual Meeting of the Society of Pediatric Liver Transplantation (SPLIT), a section of The Transplantation Society (TTS) Additional abstracts further support use of [...]

Duluth, GA – March 24, 2026 - Bridge to Life™ Ltd., a global innovator in organ preservation and perfusion technologies, today announced that Duke University Hospital became the first organ transplant [...]

Duluth, GA – March 12, 2026 - Bridge to Life™ Ltd., a global leader in organ preservation technologies for transplant medicine, announced that President and Chief Executive Officer Don Webber and Chief Financial Officer [...]

To the Organ Transplantation Community, A healthy and Happy New Year to All! Talk about starting 2026 off with a bang! We – all of us – have done it! [...]

Updated Press Release: An earlier version of this announcement was inadvertently distributed in error. This release supersedes all prior versions and reflects the Company’s accurate and complete disclosure. VitaSmart Commercial [...]

Duluth, GA – October 7, 2025 – Bridge to Life, Ltd. (BTL), a global leader in organ preservation and perfusion, today announced it has received FDA 510(k) clearance for its [...]

Chicago, IL – September 29, 2025 – Bridge to Life Ltd., a leader in organ preservation solutions and perfusion technology, today announced the appointment of David Castiglioni as Chief Commercial [...]

Chicago, IL – September 23, 2025 – Bridge to Life Ltd., a leader in organ preservation solutions and perfusion technology, today announced the appointment of Brian Lenz as Chief Financial [...]

FOR IMMEDIATE RELEASE Groundbreaking: The first multicenter study in any machine perfusion device, and the first-ever in pediatric liver transplantation. Recognition: Selected as one of six “Best Liver Abstracts” at [...]

To the Organ Transplantation Community, What an incredible week it was for Bridge to Life at the World Transplant Congress (WTC) in San Francisco, August 2–6, 2025.  Earlier this year [...]

Presentations showcased at World Transplant Congress in San Francisco demonstrate HOPE reduces the cost of liver transplantation by shortening the index hospitalization and decreasing late complications HOPE was associated with [...]

FOR IMMEDIATE RELEASE New data presented during Plenary Session at World Transplant Congress in San Francisco demonstrates HOPE improved graft and recipient survival with fewer post-transplant complications Chicago, August 4, [...]

Pivotal Findings Spotlighted in Plenary Session, Late-Breaking Presentations, and Symposium on Next-Gen Liver Preservation CHICAGO, July 15, 2025 - Bridge to Life™ Ltd., a global leader in organ preservation and [...]

To the Organ Transplantation Community, Hope this finds you all well and thriving. Many of us have just returned from the 2025 International Congress of the International Liver Transplantation Society [...]

Pivotal Findings Spotlighted in Plenary Session, Late-Breaking Presentations, and Symposium on Next-Gen Liver Preservation Chicago, June 24, 2025   Bridge to Life™ Ltd., a leader in organ preservation solutions and perfusion [...]

Chicago, May 15, 2025  Bridge to Life Ltd., a leader in organ preservation solutions and perfusion technology, today announced the presentation of nine accepted abstracts, including two late-breakers, at the 2025 International Congress of the International Liver Transplantation Society (ILTS). The conference is scheduled to take place in Singapore…

To the Organ Transplantation Community, As we all know, it’s been a wild first few weeks of the new Administration. Politics aside, it has been challenging for us all to fully understand and appreciate the ramifications of these initials acts and executive orders. We are excited to report that 2024 has indeed been a year of profound accomplishments for Bridge to Life…

To the Organ Transplantation Community, It’s hard to believe that the holiday season is upon us again. Most of us probably take this time to reflect on the past year: achievements, setbacks, ups and downs. Then we all look ahead to what will hopefully be a healthy, joyous and potentially more productive new year. We at Bridge to Life are no different…

We are excited to report that 2024 has indeed been a year of profound accomplishments for Bridge to Life. And all our achievements have been in the service of the transplantation community.

Let’s start with our “new” news, then work back through the year.

Bridge to Life Ltd., a leader in organ preservation solutions and perfusion technology, has acquired the VitaSmart Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A.. The agreement also includes exclusive global trademark rights and the ability to register the VitaSmart name worldwide…

This week, Bridge to Life celebrates a special milestone-the one-year anniversary of our office in Duluth, Georgia! This occasion marks not only a year of growth in expanding our footprint, but also the continued dedication of our entire team to advance the field of organ preservation and improve transplant outcomes…

Bridge to Life Ltd., a leading provider of organ preservation solutions and organ perfusion equipment, has announced that more than 5,000¹ liver perfusions worldwide have been successfully performed using Hypothermic Oxygenated Perfusion (HOPE) in combination with its VitaSmart2 Hypothermic Machine Perfusion…

In previous posts, I have shared my perspective on topics of interest to our transplantation community. Through these communications, I hope that you have a better sense of how committed Bridge to Life is to enhancing the preservation of organs awaiting transplantation, improving access to organs and reducing post-surgical complications. While you may know Bridge to Life as innovators in transplantation products, services, technology and research…

Bridge to Life Ltd, a global market leader in organ preservation solutions and machine perfusion technologies, and ULS Coimbra, one of the largest hospitals in Portugal with a legacy of innovation in organ transplantation, today announced a collaboration to further improve the preservation of livers…

The analysis is being presented this week at the American College of Surgeons Clinical Congress 2024 (ACS 2024) in San Francisco, California, October 19-22, 2024 Chicago, October 21, 2024   An analysis of 100 cases of liver transplantations at a Portuguese Transplant Center demonstrates that the use of Hypothermic Oxygenated PErfusion (HOPE) has the potential to lower the incidence of complications and maximizes the use of donor organs with extended criteria…

Dear Transplant Community,
We understand many of you have concerns regarding the recent challenges facing the U.S. medical device industry, including the impacts of Hurricane Helene and the Dock Workers’ Strike.
We’re pleased to inform you that Bridge to Life’s supply chain remains unaffected by these events.

The three clinical trials are discussed in oral and mini-oral presentations at the 30th International Congress of The Transplantation Society (TTS 2024) in Istanbul, Turkey, September 22-25, 2024 Chicago, September 23, 2024   Three Italian studies on HOPE (Hypothermic Oxygenated Perfusion) in liver transplantation are being presented this week at the 2024 30th Annual Meeting of the International Congress of The Transplantation Society (TTS 2024) in Istanbul, Turkey…

Mainstream media has once again reported on news relevant to the transplantation community but seems to have left out, perhaps unintentionally, a critical aspect of the story. Recently, NPR covered an organ retrieval procedure that remains scarcely used in the U.S. In the article and radio piece titled “Doctors Try a Controversial Technique to Reduce the Transplant Organ Shortage,” NPR discussed the use of normothermic regional…

Chicago, September 3, 2024 Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced acceptance of three abstracts based on data from Italian clinical trials using HOPE (Hypothermic Oxygenated Perfusion), including an oral and two mini-oral for presentation, at the 2024 30th annual meeting of the International…

To the Organ Transplantation Community,
We are just wrapping up the trifecta of Spring 2024 national and global congresses for the transplantation community: the European Liver and Intestine Transplant Association (ELITA) Summit 2024, organized by European Society for Organ Transplantation (ESOT) in April; the 2024 Annual Congress of the International Liver Transplantation Society (ILTS) in May; and now the just-completed American Transplant Congress (ATC), the Joint Annual Meeting of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation…

Chicago, June 4, 2024 – Bridge to Life Ltd, a leading provider of organ preservation solutions, has announced the latest findings from the Bridge to HOPE clinical trial, utilizing the VitaSmart Machine Perfusion System. The trial evaluates the safety and efficacy of static cold storage (SCS), the current standard for ex-vivo organ preservation, compared to SCS followed by hypothermic…

Chicago, May 8, 2024   Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced acceptance of four abstracts based on data from its U.S. pivotal clinical trial on HOPE using the VitaSmart Liver Machine, including a late-breaker, for presentation at the 2024 annual meeting of the American Transplant Congress (ATC). The conference is scheduled to take place in Philadelphia, PA from June 1-5, 2024…

Houston, May 2, 2024 Philipp Dutkowski leads the ILTS 2024 Knowledge Hub discussion on the treatment and assessment of liver grafts during hypothermic oxygenated perfusion…

Results of late-breaker Cochrane review and meta-analysis confirmed significant improvement in several parameters with HOPE compared to static cold storage and normothermic machine perfusion (NMP). While both technologies proved to be superior to SCS, there is no good evidence that NMP has the same benefits over SCS in terms of these clinically relevant…

To the Organ Transplantation Community,
In my last post , I referenced that through hypothermic oxygenated perfusion (HOPE), organs awaiting transplantation are cooled to temperatures typically ranging between 4 and 10°C, significantly reducing their metabolic rate to about 10% of normal. This oxygen-rich perfusion revitalizes the mitochondria, the powerhouse and energy reservoir of the cells. Essentially, this process primes the cells before transplantation…

Portuguese study confirms use of HOPE provides demonstrably improved liver graft utilization with reduced rates of non-anastomatic biliary stricture (NAS); Italian study demonstrates increasing experience in managing DCD (donation after circulatory determination of death) results in greater utilization of more marginal donors and transplantation in…

To the Organ Transplantation Community,
As April unfolds, National Donate Life Month comes into focus, illuminating the urgent importance of organ, eye, and tissue donation. This dedicated month honors the incredible donors and their families whose selflessness transforms lives through organ transplants. An outcome of this awareness is the increased media attention on transplantation…

Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of five accepted abstracts, including a late-breaker, at the 2024 International Congress of the International Liver Transplantation Society (ILTS). The conference is scheduled to take place in Houston, Texas, from May 1-4…

Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of two accepted abstracts at the 2024 ELITA Summit under the auspices of The European Society for Transplantation. The conference is scheduled to take place in Madrid, Spain, from April 18-20, 2024. Abstracts to be presented: 100 Hypothermic Oxygenated Perfusion liver transplants in a Portuguese Centre, Júlio Constantino, MD et a…

To the Organ Transplantation Community,
In keeping with the Bridge to Life mission and philosophy of offering premier organ transplantation products with a strong focus on product quality, innovation and accessibility in partnership with leading Transplant Centers and Organ Procurement Organizations (OPO) globally, I am excited to introduce here a periodic blog where I will update our community on Bridge to Life…

Bridge to Life Ltd, a leading provider of organ preservation solutions, today announces the return of EasiSlush™ to the US market, effective immediately. With its unmatched ease of use, high quality and portability, EasiSlush has become the preferred choice for organ transplant professionals who are responsible for transporting life-giving organs from donors to recipients under critical timelines.

Bridge to Life Ltd, a renowned market leader in cold flush organ preservation solutions, is proud to announce its recent certification for ISO 13485:2016. This achievement further solidifies the company’s commitment to maintaining exceptional standards of quality and safety in its premier products, including Belzer UW, EasiSlush^® and VitaSmart™ Machine Perfusion System (Europe).

Earlier this week Bridge to Life (BTL) became aware of the distribution of a recall notice from Krackeler Southeast Scientific LLC (KSE which was acquired by ILC Dover) to OPO’s. BTL wanted to remain transparent by providing assurance that the recall does not include BTL’s EasiSlush 0.9% Sodium Chloride Solution.

Bridge to Life Ltd. announced today its divestiture of certain assets to TransMedics, Inc., a wholly owned subsidiary of TransMedics Group, Inc., including its EVOSS heart and lung and LifeCradle heart perfusion assets.

Bridge to Life Ltd. announced results from interim analysis of its multicenter, randomized, controlled liver clinical trial presented at the 2023 American Transplant Congress (ATC).

Bridge to Life, Ltd. announced that it met positive criteria from interim analysis for early enrollment closure of its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

Bridge to Life, Ltd. announced the expansion of their executive leadership team by appointing Bob Beechey as Chief Financial Officer and Blago Herrera as Vice President of Operations.

Bridge to Life, Ltd. announced early results from its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

Steve Schweighardt, founder and former CEO to retire from daily operations but will remain as Chairman of the Board.

Bridge to Life advances their perfusion system development with the breakthrough device designation for the LifeCradle® Heart Preservation Transport system.

Bridge to Life Ltd. announced first enrollment and orthotopic liver transplantation in its U.S. pivotal Bridge to HOPE Liver Clinical Trial.

Drew David, a teenager from South Carolina, and Dr. Randy Giles, a surgeon from New Jersey, will be two of 44 organ donors honored on the annual Donate Life Rose Parade Float this January.

Bridge to Life, Ltd. announced investigational device exemption approval by the U.S. FDA for its VitaSmart™ Liver Machine Perfusion System and plans to enroll the first patient in its U.S. Bridge to HOPE Liver Clinical Trial by the end of 2021.

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the first closing of a growth financing, totaling $56 million, led by Perceptive Advisors, a leading life sciences investment firm.

Bridge to Life Chairman & CEO Stevan Schweighardt was interviewed in a feature piece for CEOCFO Magazine. He discusses the challenges of the transplant field and Bridge to Life’s current and upcoming solutions to make organ transplantations more successful.

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, and Tevosol, Inc., a clinical stage medical device startup, today announced their merger to develop and commercialize groundbreaking new products for the organ transplantation community. The arrangement includes Bridge to Life’s significant financial commitment to manufacture, trial, and launch Tevosol’s portable ex-vivo lung perfusion (EVLP) machine and normothermic organ preservation platform.

Bridge to Life is proud to have sponsored two webinars in the ILTS Insights series. Each webinar can be watched below.

A teenager from South Carolina and surgeon from New Jersey will be two of 44 organ donors honored on the annual Donate Life Rose Parade Float this January. Drew David and Dr. Randy Giles will each be memorialized with a floragraph, an artistic floral portrait. The floragraphs were made possible by We Are Sharing Hope SC, Donate Life South Carolina, and New Jersey Sharing Network, with sponsorship from Bridge to Life.

Donate Life and the South Carolina Department of Motor Vehicles held an event on April 16th at the South Carolina State House marking the 10th anniversary of Donate Life and spreading awareness of April as Donate Life Month.

A teenager from South Carolina and surgeon from New Jersey will be two of 44 organ donors honored on the annual Donate Life Rose Parade Float this January. Drew David and Dr. Randy Giles will each be memorialized with a floragraph, an artistic floral portrait. The floragraphs were made possible by We Are Sharing Hope SC, Donate Life South Carolina, and New Jersey Sharing Network, with sponsorship from Bridge to Life.

A smartphone app designed to draw the interest of younger people was developed by the Kentucky Organ Donor Affiliates (KODA) with funding from a Bridge to Life grant. The app, named “Bridge2Life”, attempts to meet the challenge of growing the donation registry in an age when younger people no longer obtain driver’s licenses so readily and tend to consult social media for information about life’s issues. The app has been widely applauded in its nation-wide tour promoting Growing the Registry, most recently by winning the AATB Groundbreaker Award in Dallas, Oct 12.